Search
Dibromothymoquinone
go.drugbank.com/drugs/DB04646ExperimentalAt low concentrations, this compound inhibits reduction of conventional hydrophilic electron acceptors, probably acting as a plastoquinone antagonist. … At higher concentrations, it acts as an electron acceptor, intercepting electrons either before or at the site of its inhibitory activity. [PubChem]
Nitarsone
go.drugbank.com/drugs/DB11437ExperimentalVet approvedIt is used as an additive in poultry feed to improve weight gain and feed efficiency, while preventing blackhead disease. It is marketed as Histostat by Zoetis, a publicly traded subsidiary of Pfizer.
Resatorvid
go.drugbank.com/drugs/DB05943InvestigationalResatorvid is an investigational compound designed for the treatment of severe sepsis.
XP21279
go.drugbank.com/drugs/DB06319InvestigationalXP21279 was under investigation in clinical trial NCT00914602 (An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects), administered in combination with [Carbidopa
Allovectin-7
go.drugbank.com/drugs/DB17439InvestigationalIt was discontinued after it failed to improve the objective response rate or overall survival versus first-line chemotherapy in malignant melanoma.[A255207]
Pamufetinib
go.drugbank.com/drugs/DB20752InvestigationalPamufetinib has a monoisotopic molecular weight of 518.14 Da.
Gold
go.drugbank.com/drugs/DB14154InvestigationalIt is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
Tridecactide
go.drugbank.com/drugs/DB15687Investigational[A203210] Tridecactide, along with [metenkefalin], are under investigation as an immunomodulatory therapy for moderate to severe COVID-19.[L13874,L13877] … Tridecactide, also known as alpha-corticotropin 1-13, is a deacetylated and deaminated alpha-melanocyte stimulating hormone, which may have antipyretic, anti-inflammatory, and antimicrobial effects.
Bifeprunox
go.drugbank.com/drugs/DB04888InvestigationalBifeprunox is a novel atypical antipsychotic agent which, along with SLV313, aripiprazole and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.